For research use only. Not for therapeutic Use.
Lys(CO-C3-p-I-Ph)-O-tBu (Cat No.: I040016) is a chemically modified lysine derivative used in peptide synthesis, medicinal chemistry, and drug development. The presence of a para-iodophenyl (p-I-Ph) group allows for bioorthogonal conjugation and radiolabeling applications, making it valuable in imaging and targeted therapy research. The tert-butyl (O-tBu) protecting group enhances stability and solubility during synthetic processes. This compound is widely used in designing peptide-based probes, radiopharmaceuticals, and novel therapeutic agents in cancer, metabolic disease, and biomedical research.
| CAS Number | 2703051-80-1 |
| Synonyms | tert-butyl (2S)-2-amino-6-[4-(4-iodophenyl)butanoylamino]hexanoate |
| Molecular Formula | C20H31IN2O3 |
| Purity | ≥95% |
| InChI | InChI=1S/C20H31IN2O3/c1-20(2,3)26-19(25)17(22)8-4-5-14-23-18(24)9-6-7-15-10-12-16(21)13-11-15/h10-13,17H,4-9,14,22H2,1-3H3,(H,23,24)/t17-/m0/s1 |
| InChIKey | BTKQPZFZKRZXTN-KRWDZBQOSA-N |
| SMILES | CC(C)(C)OC(=O)C(CCCCNC(=O)CCCC1=CC=C(C=C1)I)N |
| Reference | [1]. Sun M, et al. Prostate-Specific Membrane Antigen (PSMA)-Targeted Radionuclide Therapies for Prostate Cancer. Curr Oncol Rep. 2021 Mar 29;23(5):59. [2]. Zitzmann-Kolbe S, et al., Preclinical evaluation of an actinium-225 labeled PSMA-targeting small molecule (225Ac-PSMA-Trillium (BAY 3563254)) for the treatment of metastatic castration resistant prostate cancer (mCRPC)[J]. Cancer Research, 2024, 84(6_Supplement): 6033-6033. |
